Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E21.74 EPS (ttm)3.72 Insider Own0.07% Shs Outstand1.49B Perf Week1.48%
Market Cap120.85B Forward P/E8.58 EPS next Y9.42 Insider Trans-21.14% Shs Float1.49B Perf Month-5.49%
Income5.69B PEG2.29 EPS next Q2.04 Inst Own72.20% Short Float1.88% Perf Quarter-8.35%
Sales32.75B P/S3.69 EPS this Y-2.40% Inst Trans0.12% Short Ratio3.94 Perf Half Y-17.03%
Book/sh-1.92 P/B- EPS next Y8.31% ROA9.60% Target Price93.88 Perf Year-28.50%
Cash/sh5.88 P/C13.76 EPS next 5Y9.51% ROE- 52W Range75.77 - 122.00 Perf YTD-12.30%
Dividend4.28 P/FCF19.81 EPS past 5Y1.20% ROI17.80% 52W High-33.73% Beta1.17
Dividend %5.29% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin76.40% 52W Low6.70% ATR1.94
Employees30000 Current Ratio1.20 Sales Q/Q249.50% Oper. Margin31.00% RSI (14)46.52 Volatility1.53% 2.44%
OptionableYes Debt/Eq- EPS Q/Q387.90% Profit Margin19.60% Rel Volume0.88 Prev Close80.52
ShortableYes LT Debt/Eq- EarningsJan 25 BMO Payout72.90% Avg Volume7.12M Price80.85
Recom2.70 SMA20-0.91% SMA50-5.23% SMA200-12.16% Volume6,291,400 Change0.41%
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-16-19 10:04AM  These 3 Value Stocks Are Absurdly Cheap Right Now Motley Fool
Feb-15-19 04:16PM  AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc. Moody's
08:01AM  [$$] WSJ Tax Guide 2019: The Drug Industry The Wall Street Journal
Feb-13-19 09:15AM  AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? Zacks
Feb-12-19 09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
05:00AM  5 Aristocrats for Stable Income MoneyShow
Feb-11-19 03:24PM  5 High-Growth Stocks Undervalued by the Market InvestorPlace
02:46PM  Here's Why Coherus BioSciences Rose 48.7% in January Motley Fool
08:00AM  AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma PR Newswire
Feb-09-19 09:00AM  Here's Why AbbVie's Stock Tanked in January Motley Fool
Feb-08-19 01:58PM  Does FedEx look good here? What's the deal with McKesson? Buy Abbvie? CNBC Videos
Feb-06-19 08:43PM  Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:52PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
01:33PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
12:16PM  Congress invites 7 drugmakers to testify at potentially hostile hearing on drug prices. Here's what they're saying CNBC
Feb-05-19 08:01PM  Flip the Script: Drugmakers Blame Middlemen for Price Increases The Wall Street Journal
04:06PM  Merck CEO Frazier to testify at Senate drug pricing hearing Reuters
03:02PM  3 Biotech Stocks That Pay Solid Dividends InvestorPlace
12:00PM  3 Red-Hot Stocks (And 3 That Arent) InvestorPlace
11:38AM  Pharma execs will testify before Congress 'one way or another,' US senator says CNBC
10:53AM  Top Marijuana Stocks That Pay Dividends Investopedia
08:07AM  Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies Zacks
06:00AM  Flip the Script: Drugmakers Blame Middlemen for Price Increases The Wall Street Journal
12:30AM  Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm PR Newswire
Feb-04-19 07:31AM  AbbVie Falls 3%
Feb-03-19 10:40AM  Bulls & Bears Of The Week: AT&T, Facebook, GE, Microsoft And More Benzinga
09:06AM  Is AbbVie a Buy? Motley Fool
Feb-02-19 02:17PM  Pricing Pressure a Hard Pill for Pharma to Swallow
07:33AM  Better Buy: Johnson & Johnson vs. AbbVie Motley Fool
Feb-01-19 04:50PM  Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance Zacks
08:52AM  The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics Zacks
08:15AM  Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY Zacks
05:00AM  The 12 Best Dividend Aristocrats- Part 1 MoneyShow
Jan-31-19 12:39PM  Top Research Reports for Union Pacific, AbbVie & General Dynamics Zacks
Jan-30-19 10:19AM  ABBV Stock Is Worth a Look at Multi-Year Lows InvestorPlace
09:49AM  Genentech kills big drug study in early Alzheimer's patients American City Business Journals
08:16AM  3 Big Pharmas Expecting a Softer 2019 Motley Fool
07:16AM  Jim Cramer Gives His Opinion On AbbVie, Idexx Labs And More Benzinga
Jan-29-19 10:54PM  Edited Transcript of ABBV earnings conference call or presentation 25-Jan-19 2:00pm GMT Thomson Reuters StreetEvents
06:55PM  Cramer's lightning round: AbbVie needs to make an acquisitionit might just save its stock CNBC
05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
03:48PM  10 Value Stocks to Buy for 2019 and Beyond Kiplinger
12:29PM  Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
10:42AM  Jacksonville's increasing use of LNG as a transportation fuel American City Business Journals
10:00AM  3 Top Dividend Stocks to Buy Right Now Motley Fool
09:15AM  AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting Zacks
07:25AM  The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive Benzinga
Jan-28-19 12:10PM  Is AbbVie in Hot Water?
10:59AM  Analysts Cut AbbVie Price Targets After Earnings Miss Benzinga
10:19AM  Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN Zacks
10:07AM  The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck Zacks
09:15AM  This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
07:00AM  AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients PR Newswire
05:38AM  AbbVie Falls 3%
Jan-27-19 07:16PM  3 Reasons AbbVie Investors Aren't Too Worried About Humira Anymore Motley Fool
07:03AM  Forget Humira -- Here's What You Need to Know About AbbVie Motley Fool
Jan-25-19 04:37PM  Western Digital, Starbucks rise while AbbVie, Intel drop Associated Press -6.22%
04:35PM  Why Intel, AbbVie, and Vale Slumped Today Motley Fool
04:17PM  AbbVie Stock Crumbles After Biosimilars Take A Chunk Of Humira Sales Investor's Business Daily
04:10PM  AbbVie Falls After Missing Top- and Bottom-Line Estimates
02:15PM  AbbVie Inc (ABBV) Q4 2018 Earnings Conference Call Transcript Motley Fool
01:45PM  AbbVie Q4 Earnings: 3 Key Things You Need to Know Motley Fool
12:00PM  Celgene Stock Is Rising After the CEO of AbbVie Ruled Out a Big Deal
11:15AM  [$$] Drug Maker AbbVie Swings to Loss on Charge from Stemcentrx Deal The Wall Street Journal
11:05AM  AbbVie Earnings: ABBV Stock Falters on Q4 Miss InvestorPlace
11:05AM  AbbVie expects steeper decline in Humira's overseas sales; shares fall Reuters
10:41AM  Congressional Activities on Shutdown in Focus Zacks
10:34AM  AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down Zacks
10:28AM  Asia, Congress Activity, Put Futures in the Green Zacks
10:23AM  Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV Zacks
09:44AM  AbbVie not contemplating big deals - CEO Reuters
09:03AM  US STOCKS-Wall St set to open higher as investors focus on upbeat earnings Reuters
09:02AM  AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down Zacks
09:00AM  AbbVie (ABBV) Lags Q4 Earnings and Revenue Estimates Zacks
08:00AM  AbbVie: 4Q Earnings Snapshot Associated Press
07:52AM  Abbvie shares slide 2.3% premarket after earnings miss MarketWatch
07:49AM  AbbVie profit misses as Humira faces biosimilar challenge in Europe Reuters
07:45AM  AbbVie profit misses as Humira faces biosimilar challenge in Europe Reuters
07:42AM  AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results PR Newswire
02:46AM  AbbVie Earnings, Revenue miss in Q4
Jan-24-19 07:29PM  Can Allergan (AGN) Keep the Earnings Streak Alive in Q4? Zacks
04:34PM  Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? Zacks
02:02PM  Q4 Earnings Preview For AbbVie Benzinga
01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
11:17AM  Pfizer (PFE) to Report Q4 Earnings: What's in the Cards? Zacks
10:59AM  Healthcare ETFs in Focus Ahead of Q4 Earnings Zacks
10:47AM  The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb Zacks
10:44AM  Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie Zacks
10:27AM  Is a Surprise Coming for AbbVie (ABBV) This Earnings Season? Zacks
08:15AM  3 Things to Expect in AbbVie's Q4 Earnings Update Motley Fool
08:13AM  AbbVie Falls 3%
Jan-23-19 02:32PM  Top Research Reports for Amazon, Verizon & AbbVie Zacks
09:31AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
Jan-22-19 11:22AM  5 Amazing Earnings Charts Zacks
09:57AM  J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft Zacks
08:31AM  Bet on These 5 Low Leverage Stocks to Secure Returns Zacks
06:06AM  Better Buy: Pfizer vs. AbbVie Motley Fool
Jan-21-19 02:08PM  AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study Zacks
08:23AM  Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill Zacks
07:50AM  What's in Store for Bristol-Myers (BMY) in Q4 Earnings? Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Universite de Montreal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; and Tizona Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM